Abbott Reports (AVEIR DR i2i) Study Results of Aveir Dual-Chamber Leadless Pacemaker System
Shots:
- The (AVEIR DR i2i) IDE study evaluates AVEIR DR leadless pacemakers in 300 patients through 3mos. post-implant across 55 centers in the US, Canada & EU
- The study met its 3 prespecified 1EPs i.e., 98.3% implant success rate & the study also achieved the safety EPs, ≥97% of patients had successful AV synchrony which means that the upper and lower chambers were beating normally despite different types of underlying slow heart rhythms
- Aveir DR could offer new benefits for those with slower-than-normal heart rhythms & the results were presented at HRS 2023 & published in the NEJM. Aveir DR delivers electrical impulses to the heart muscle via thin, insulated wires, known as cardiac leads that restore the normal heart rhythm
Ref: Abbott | Image: Abbott
Related News:- Abbott’s Assert-IQ Insertable Cardiac Monitor Receives the US FDA’s Clearance for Irregular Heartbeats
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
